N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor

British Journal of Pharmacology

Volumn 173, Issue 5, 2016, Pages 826-838

  Hansen, L S ^a,b   Sparre Ulrich, A H ^a   Christensen, M ^b   Knop, F K ^a,b   Hartmann, B ^a,b   Holst, J J ^a,b   Rosenkilde, M M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; IODINE 125; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CARBOXY TERMINAL SEQUENCE; COMPETITIVE INHIBITION; COS 7 CELL LINE; GENETIC TRANSFECTION; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR BINDING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHLOROCEBUS AETHIOPS; COS CELL LINE; GENETICS; HUMAN; METABOLISM;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; PEPTIDE FRAGMENTS; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 84958757768     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13384     Document Type: Article

References (67)

1. Al-Sabah S, Al-Fulaij M, Ahmed HA, (2014). Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells. Eur J Pharmacol 741: 311-315.
2. Alaña I, Parker JC, Gault VA, Flatt PR, O'harte FPM, Malthouse JP, et al,. (2006). NMR and alanine scan studies of glucose-dependent insulinotropic polypeptide in water. Journal of Biological Chemistry 281: 16370-16376.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al,. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
4. Asmar M, Simonsen L, Arngrim N, Holst JJ, Dela F, Bulow J, (2014). Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects. Int J Obes 38: 259-265.
5. Baggio LL, Drucker DJ, (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157.
6. Brubaker PL, Drucker DJ, (2002). Structure-function of the glucagon receptor family of G protein-coupled receptors: The glucagon, GIP, GLP-1, and GLP-2 receptors. Recept Channel 8: 179-188.
7. Campbell JE, Drucker DJ, (2013). Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17: 819-837.
8. Christensen M, Vedtofte L, Holst JJ, Vilsboell T, Knop FK, (2011). Glucose-dependent insulinotropic polypeptide: A bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60: 3103-3109.
9. Clark-Lewis I, Kim KS, Rajarathnam K, Gong JH, Dewald B, Moser B, et al,. (1995). Structure-activity relationships of chemokines. J Leukoc Biol 57: 703-711.
10. Deacon CF, (2004). Circulation and degradation of GIP and GLP-1. Horm Metab Res 36: 761-765.
11. Deacon CF, Plamboeck A, Rosenkilde MM, De HJ, Holst JJ, (2006). GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. Am J Physiol Endocrinol Metab 291: E468-E475.
12. Deblasi A, O'reilly K, Motulsky HJ, (1989). Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci 10: 227-229.
13. Fujita Y, Asadi A, Yang GK, Kwok YN, Kieffer TJ, (2010a). Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut. Am J Physiol Gastrointest Liver Physiol 298: G608-G614.
14. Fujita Y, Wideman RD, Asadi A, Yang GK, Baker R, Webber T, et al,. (2010b). Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. Gastroenterology 138: 1966-1975.
15. Gallwitz B, Witt M, Folsch UR, Creutzfeldt W, Schmidt WE, (1993). Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells. J Mol Endocrinol 10: 259-268.
16. Gaudin-Audrain C, Irwin N, Mansur S, Flatt PR, Thorens B, Baslé M, et al,. (2013). Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice. Bone 53: 221-230.
17. Gault VA, Harriott P, Flatt PR, O'harte FP, (2002a). Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide. Biosci Rep 22: 523-528.
18. Gault VA, O'harte FPM, Harriott P, Flatt PR, (2002b). Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Comm 290: 1420-1426.
19. Gault VA, Parker JC, Harriott P, Flatt PR, O'harte FP, (2002c). Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol 175: 525-533.
20. Gault VA, Porter DW, Irwin N, Flatt PR, (2011). Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice. J Endocrinol 208: 265-271.
21. Gelling RW, Coy DH, Pederson RA, Wheeler MB, Hinke S, Kwan T, et al,. (1997). GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro. Regul Pept 69: 151-154.
22. Hinke SA, Manhart S, Pamir N, Demuth HU, Gelling W, Pederson RA, et al,. (2001). Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). Biochimica et Biophysica Acta (BBA)-Protein Struct Mol Enzymol 1547: 143-155.
23. Hinke SA, Manhart S, Speck M, Pederson RA, Demuth HU, Mcintosh CHS, (2004). In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide. Life Sci 75: 1857-1870.
24. Hjorth SA, Schwartz TW, (1996). Glucagon and GLP-1 receptors: Lessons from chimeric ligands and receptors. Acta Physiologica Scandinavica 157: 343-345.
25. Holst JJ, Bersani M, (1991). 1-assays for peptide products of somatostatin gene expression. In:, Conn PM, (ed.). Methods in Neurosciences. Academic Press.
26. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S, (2011). Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 34 (Suppl 2): S251-S257.
27. Irwin N, Green BD, Parker JC, Gault VA, O'harte FPM, Flatt PR, (2006a). Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16). Regul Pept 135: 45-53.
28. Irwin N, O'harte FP, Gault VA, Green BD, Greer B, Harriott P, et al,. (2006b). GIP(Lys16PAL) and GIP(Lys37PAL): Novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J Med Chem 49: 1047-1054.
29. Jensen PC, Thiele S, Ulven T, Schwartz TW, Rosenkilde MM, (2008). Positive versus negative modulation of different endogenous chemokines for CC-chemokine receptor 1 by small molecule agonists through allosteric versus orthosteric binding. J Biol Chem 283: 23121-23128.
30. Jorgensen R, Kubale V, Vrecl M, Schwartz TW, Elling CE, (2007). Oxyntomodulin differentially affects glucagon-like peptide-1 receptor +Ý-arrestin recruitment and signaling through G+Ý. J Pharmacol Exp Therapeut 322: 148-154.
31. Kerr BD, Flatt AJS, Flatt PR, Gault VA, (2011). Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Comm 404: 870-876.
32. Kissow H, Hartmann B, Holst JJ, Viby N-E, Hansen LS, Rosenkilde MM, et al,. (2012). Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept 179: 91-100.
33. Knop FK, Vilsboll T, Holst JJ, (2009). Incretin-based therapy of type 2 diabetes mellitus. Curr Protein Pept Sci 10: 46-55.
34. Kreymann B, Williams G, Ghatei MA, Bloom SR, (1987). Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 2: 1300-1304.
35. Kubota A, Yamada Y, Yasuda K, Someya Y, Ihara Y, Kagimoto S, et al,. (1997). Gastric inhibitory polypeptide activates MAP kinase through the wortmannin-sensitive and -insensitive pathways. Biochem Biophys Res Commun 235: 171-175.
36. Lazareno S, Birdsall NJ, (1993). Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br J Pharmacol 109: 1110-1119.
37. Malde AK, Srivastava SS, Coutinho EC, (2007). Understanding interactions of gastric inhibitory polypeptide (GIP) with its G-protein coupled receptor through NMR and molecular modeling. J Pept Sci 13: 287-300.
38. Maletti M, Carlquist M, Portha B, Kergoat M, Mutt V, Rosselin G, (1986). Structural requirements for gastric inhibitory polypeptide (GIP) receptor binding and stimulation of insulin release. Peptides 7 (Supplement 1): 75-78.
39. Mentlein R, (1999). Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85: 9-24.
40. Mentlein R, (2009). Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab 23: 443-452.
41. Mentlein R, Gallwitz B, Schmidt WE, (1993). Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835.
42. Mieczkowska A, Irwin N, Flatt PR, Chappard D, Mabilleau G, (2013). Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. Bone 56: 337-342.
43. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al,. (2002). Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8: 738-742.
44. Moroder LHA, Thamm P, Wilschowitz L, Brown JC, Wünsch E, (1978). Studies on gastric inhibitory polypeptide: Synthesis of the octatricontapeptide GIP(1-38) with full insulinotropic activity. Scand J Gastroenterol 13 suppl. 49: P. 129.
45. Morrow GW, Kieffer TJ, Mcintosh CH, Macgillivray RT, Brown JC, St Pierre S, et al,. (1996). The insulinotropic region of gastric inhibitory polypeptide; fragment analysis suggests the bioactive site lies between residues 19 and 30. Can J Physiol Pharmacol 74: 65-72.
46. Nakamura T, Tanimoto H, Mizuno Y, Tsubamoto Y, Noda H, (2012). Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo. Diabetes Obes Metab 14: 511-517.
47. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, et al,. (1986). Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498.
48. Nissen A, Christensen M, Knop FK, Vilsbøll T, Holst JJ, Hartmann B, (2014). Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metabol 99: E2325-E2329.
49. Parthier C, Kleinschmidt M, Neumann P, Rudolph R, Manhart S, Schlenzig D, et al,. (2007). Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci U S A 104: 13942-13947.
50. Pathak V, Gault VA, Flatt PR, Irwin N, (2015a). Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice. Mol Cell Endocrinol 401: 120-129.
51. Pathak V, Vasu S, Gault VA, Flatt PR, Irwin N, (2015b). Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice. Diabetologia 58: 2144-2153.
52. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al,. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: An expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
53. Pederson RA, Brown JC, (1976). The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 99: 780-785.
54. Ravn P, Madhurantakam C, Kunze S, Matthews E, Priest C, O'brien S, et al,. (2013). Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. J Biol Chem 288: 19760-19772.
55. Rosenkilde MM, Cahir M, Gether U, Hjorth SA, Schwartz TW, (1994). Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding. J Biol Chem 269: 28160-28164.
56. 2 fragment with potent pancreatic amylase inhibitory activity. Regul Pept 39: 9-17.
57. Sandberg E, Ahren B, Tendler D, Carlquist M, Efendic S, (1986). Potentiation of glucose-induced insulin secretion in the perfused rat pancreas by porcine GIP (gastric inhibitory polypeptide), bovine GIP, and bovine GIP(1-39). Acta Physiol Scand 127: 323-326.
58. Sparre-Ulrich AH, Hansen LS, Svendsen B, Christensen M, Knop FK, Hartmann B, et al,. (2015). Species-specific action of (Pro3)GIP-an efficacious agonist on human GIP receptor, but partial agonist and competitive antagonist on rat and mouse GIP receptors. Br J Pharmacol.
59. Thiele S, Rosenkilde MM, (2014). Interaction of chemokines with their receptors-from initial chemokine binding to receptor activating steps. Curr Med Chem 21: 3594-3614.
60. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C, (1993). Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682.
61. Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM, (1996). Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 98: 2440-2445.
62. Tseng CC, Zhang XY, Wolfe MM, (1999). Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am J Physiol 276: E1049-E1054.
63. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI, (1993). Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133: 2861-2870.
64. Vilardaga JP, Romero G, Friedman PA, Gardella TJ, (2011). Molecular basis of parathyroid hormone receptor signaling and trafficking: A family B GPCR paradigm. Cell Mol Life Sci 68: 1-13.
65. Wheeler MB, Gelling RW, Mcintosh CH, Georgiou J, Brown JC, Pederson RA, (1995). Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: Ligand binding and intracellular signaling properties. Endocrinology 136: 4629-4639.
66. Yaqub T, Tikhonova IG, Lättig J, Magnan R, Laval M, Escrieut C, et al,. (2010). Identification of determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand. Mol Pharmacol 77: 547-558.
67. Zhong Q, Bollag RJ, Dransfield DT, Gasalla-Herraiz J, Ding KH, Min L, et al,. (2000). Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells. Peptides 21: 1427-1432.